Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...

Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.

Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...

Capricor Therapeutics (CAPR) just delivered positive topline data from its pivotal Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy, a key late stage milestone that immediately ...

Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

US rare diseases focused biotech Capricor Therapeutics shares closed up 371% at $29.96, having leapt a staggering 500% ...

In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with ...

Capricor Therapeutics reported positive data from its phase three study of its Deramiocel therapy to treat Duchenne muscular dystrophy. The company said the study met the primary endpoint and the key ...